UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Time to first transfusion in lower-risk patients with myelodysplastic neoplasia (MDS) is another prognostic factor of survival

Leukemia & lymphoma, 2023-07, Vol.ahead-of-print (ahead-of-print), p.1-4

2023

Volltextzugriff (PDF)

Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study

Annals of oncology, 2019-05, Vol.30, p.iii50-iii50

2019

Volltextzugriff (PDF)

Safety of acalabrutinib treatment in very old (≥80 y) and/or frail patients with chronic lymphocytic leukemia ‐ interim safety analysis of the ongoing phase II CLL‐Frail trial

Hematological oncology, 2023-06, Vol.41 (S2), p.468-469

2023

Volltextzugriff (PDF)

IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAïVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE CLL12 TRIAL

Hematological oncology, 2023-06, Vol.41 (S2), p.56-58

2023

Volltextzugriff (PDF)

Combination Chemotherapy With Gemcitabine Plus Oxaliplatin in Patients With Intensively Pretreated or Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group

Journal of clinical oncology, 2004-01, Vol.22 (1), p.108-114

2004

Volltextzugriff (PDF)

Therapie primärer Magenlymphome

Der Onkologe, 2011-09, Vol.17 (9), p.814-817

2011

Volltextzugriff (PDF)

Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia

Leukemia, 2007-09, Vol.21 (9), p.1901-1906

2007

Volltextzugriff (PDF)

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

Annals of oncology, 2021-08, Vol.32 (8), p.994-1004

2021

Volltextzugriff (PDF)

PDGF and vessel maturation

Recent results in cancer research, 2010-01, Vol.180, p.103

2010

Volltextzugriff (PDF)

Stage-adapted Radiation Therapy for Treatment of Localized Gastric Marginal Zone Lymphoma in 326 Patients: Results of the German Study Group on Gastrointestinal Lymphoma (DSGL)

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S72-S72

2012

Volltextzugriff (PDF)

High-dose chemotherapy with autologous PBSC transplantation for poor prognosis germ cell tumors: a retrospective monocenter analysis of 44 cases

Bone marrow transplantation (Basingstoke), 2012-10, Vol.47 (10), p.1321-1325

2012

Volltextzugriff (PDF)

Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens

Annals of oncology, 2008-03, Vol.19 (3), p.538-544

2008

Volltextzugriff (PDF)

1212P IMpower010: Characterisation of patients (pts) with stage II-IIIA PD-L1 TC≥50% NSCLC who were disease-free at 5 years (5yDF) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after resection and adjuvant (adj) chemotherapy (chemo)

Annals of oncology, 2024-09, Vol.35, p.S780-S781

2024

Volltextzugriff (PDF)

1211P IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)

Annals of oncology, 2024-09, Vol.35, p.S779-S780

2024

Volltextzugriff (PDF)

1264MO IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)

Annals of oncology, 2023-10, Vol.34, p.S732-S733

2023

Volltextzugriff (PDF)

Treatment Results in Localized Primary Gastric Lymphoma: Data of Patients Registered Within the German Multicenter Study (GIT NHL 02/96)

Journal of clinical oncology, 2005-10, Vol.23 (28), p.7050-7059

2005

Volltextzugriff (PDF)

80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study

Annals of oncology, 2022-04, Vol.33, p.S71

2022

Volltextzugriff (PDF)

2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC

Annals of oncology, 2021-12, Vol.32, p.S1374

2021

Volltextzugriff (PDF)

LBA9 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC

Annals of oncology, 2021-09, Vol.32, p.S1319-S1319

2021

Volltextzugriff (PDF)

MA11.08 IMpower010: Exploratory Analysis of Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S139

2023

Volltextzugriff (PDF)

Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study

Annals of oncology, 2019-10, Vol.30, p.v135

2019

Volltextzugriff (PDF)

371P - Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study

Annals of oncology, 2019-10, Vol.30, p.v135-v135

2019

Volltextzugriff (PDF)

371PPalbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1533P Real-life data from the platform for outcome, quality of life and translational research on pancreatic cancer - PARAGON

Annals of oncology, 2020-09, Vol.31, p.S943-S943

2020

Volltextzugriff (PDF)

156PPalbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study

Annals of oncology, 2019-05, Vol.30 (Supplement_3)

2019

Volltextzugriff (PDF)

1 – 25 von 198

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(162)
Mit Volltextzugriff
(160)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(63)
Science & Technology
(62)
Life Sciences & Biomedicine
(57)
Oncology
(40)
Female
(27)
Male
(25)
Biological And Medical Sciences
(23)
Adult
(19)
Medical Sciences
(18)
Middle Aged
(18)
Hematology
(17)
Aged
(15)
Animals
(15)
Tumors
(13)
Child
(10)
Angiogenesis Inhibitors - Therapeutic Use
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Infant
(9)
Neoplasms - Drug Therapy
(9)
Disease-Free Survival
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Time to first transfusion in lower-risk patients with myelodysplastic neoplasia (MDS) is another prognostic factor of survival

Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study

Safety of acalabrutinib treatment in very old (≥80 y) and/or frail patients with chronic lymphocytic leukemia ‐ interim safety analysis of the ongoing phase II CLL‐Frail trial

IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAïVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE CLL12 TRIAL

Combination Chemotherapy With Gemcitabine Plus Oxaliplatin in Patients With Intensively Pretreated or Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group

Therapie primärer Magenlymphome

Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

PDGF and vessel maturation

Stage-adapted Radiation Therapy for Treatment of Localized Gastric Marginal Zone Lymphoma in 326 Patients: Results of the German Study Group on Gastrointestinal Lymphoma (DSGL)

High-dose chemotherapy with autologous PBSC transplantation for poor prognosis germ cell tumors: a retrospective monocenter analysis of 44 cases

Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens

1212P IMpower010: Characterisation of patients (pts) with stage II-IIIA PD-L1 TC≥50% NSCLC who were disease-free at 5 years (5yDF) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after resection and adjuvant (adj) chemotherapy (chemo)

1211P IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)

1264MO IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)

Treatment Results in Localized Primary Gastric Lymphoma: Data of Patients Registered Within the German Multicenter Study (GIT NHL 02/96)

80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study

2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC

LBA9 IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC

MA11.08 IMpower010: Exploratory Analysis of Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC

Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study

371P - Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study

371PPalbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study

1533P Real-life data from the platform for outcome, quality of life and translational research on pancreatic cancer - PARAGON

156PPalbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase II study

Suchergebnisse filtern